Neuropeptides as Targets for the Development of Anticonvulsant Drugs

Molecular Neurobiology

Volumn 50, Issue 2, 2014, Pages 626-646

  Clynen, Elke ^a   Swijsen, Ann ^a   Raijmakers, Marjolein ^a,b   Hoogland, Govert ^b   Rigo, Jean Michel ^a  

^a HASSELT UNIVERSITY   (Belgium)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Animal seizure models; Antiepileptic drugs; Epilepsy; Febrile seizures; Neuropeptides; Seizures

Indexed keywords

ANGIOTENSIN DERIVATIVE; ANTICONVULSIVE AGENT; ARGIPRESSIN; BETA ENDORPHIN; CHOLECYSTOKININ; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTISTATIN; DYNORPHIN; ENKEPHALIN; GALANIN; GHRELIN; GHRELIN RECEPTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; MELANIN CONCENTRATING HORMONE; NESFATIN 1 PROTEIN; NEUROPEPTIDE; NEUROPEPTIDE Y; NEUROTENSIN; OXYTOCIN; PROTEIN; PROTIRELIN; SOMATOSTATIN; TACHYKININ; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANTICONVULSANT ACTIVITY; DISEASE SEVERITY; EPILEPSY; EPILEPTOGENESIS; HUMAN; INFANTILE SPASM; NERVOUS SYSTEM DEVELOPMENT; NEUROTRANSMISSION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; PYRAMIDAL NERVE CELL; REVIEW; SEIZURE; SEIZURE SUSCEPTIBILITY; UPREGULATION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; NERVE CELL;

ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; EPILEPSY; HUMANS; NEURONS; NEUROPEPTIDES;

EID: 84911007352     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8669-x     Document Type: Review

References (217)

1. Weaver DF, Pohlmann-Eden B (2013) Pharmacoresistant epilepsy: unmet needs in solving the puzzle(s). Epilepsia 54(Suppl 2):80–85
2. Dobolyi A, Kekesi KA, Juhasz G, Szekely AD, Lovas G, Kovacs Z (2014) Receptors of peptides as therapeutic targets in epilepsy research. Curr Med Chem 21:764–787
3. Kovac S, Walker MC (2013) Neuropeptides in epilepsy. Neuropeptides 47:467–475
4. Mytinger JR, Joshi S (2012) The current evaluation and treatment of infantile spasms among members of the Child Neurology Society. J Child Neurol 27:1289–1294
5. Tsao CY (2009) Current trends in the treatment of infantile spasms. Neuropsychiatr Dis Treat 5:289–299
6. Matsumoto A, Kumagai T, Takeuchi T, Miyazaki S, Watanabe K (1987) Clinical effects of thyrotropin-releasing hormone for severe epilepsy in childhood: a comparative study with ACTH therapy. Epilepsia 28:49–55
7. Takeuchi Y, Takano T, Abe J, Takikita S, Ohno M (2001) Thyrotropin-releasing hormone: role in the treatment of West syndrome and related epileptic encephalopathies. Brain Dev 23:662–667
8. Furtinger S, Pirker S, Czech T, Baumgartner C, Ransmayr G, Sperk G (2001) Plasticity of Y1 and Y2 receptors and neuropeptide Y fibers in patients with temporal lobe epilepsy. J Neurosci 21:5804–5812
9. Cardoso A, Freitas-da-Costa P, Carvalho LS, Lukoyanov NV (2010) Seizure-induced changes in neuropeptide Y-containing cortical neurons: Potential role for seizure threshold and epileptogenesis. Epilepsy Behav 19:559–567
10. Poulsen FR, Jahnsen H, Blaabjerg M, Zimmer J (2002) Pilocarpine-induced seizure-like activity with increased BNDF and neuropeptide Y expression in organotypic hippocampal slice cultures. Brain Res 950:103–118
11. Vezzani A, Schwarzer C, Lothman EW, Williamson J, Sperk G (1996) Functional changes in somatostatin and neuropeptide Y containing neurons in the rat hippocampus in chronic models of limbic seizures. Epilepsy Res 26:267–279
12. de Lanerolle NC, Kim JH, Robbins RJ, Spencer DD (1989) Hippocampal interneuron loss and plasticity in human temporal lobe epilepsy. Brain Res 495:387–395
13. Gobbi M, Gariboldi M, Piwko C, Hoyer D, Sperk G, Vezzani A (1998) Distinct changes in peptide YY binding to, and mRNA levels of, Y1 and Y2 receptors in the rat hippocampus associated with kindling epileptogenesis. J Neurochem 70:1615–1622
14. Kofler N, Kirchmair E, Schwarzer C, Sperk G (1997) Altered expression of NPY-Y1 receptors in kainic acid induced epilepsy in rats. Neurosci Lett 230:129–132
15. Schwarzer C, Kofler N, Sperk G (1998) Up-regulation of neuropeptide Y-Y2 receptors in an animal model of temporal lobe epilepsy. Mol Pharmacol 53:6–13
16. Erickson JC, Clegg KE, Palmiter RD (1996) Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 381:415–421
17. Vezzani A, Michalkiewicz M, Michalkiewicz T, Moneta D, Ravizza T, Richichi C, Aliprandi M, Mule F, Pirona L, Gobbi M, Schwarzer C, Sperk G (2002) Seizure susceptibility and epileptogenesis are decreased in transgenic rats overexpressing neuropeptide Y. Neuroscience 110:237–243
18. Noé F, Frasca A, Balducci C, Carli M, Sperk G, Ferraguti F, Pitkänen A, Bland R, Fitzsimons H, During M, Vezzani A (2009) Neuropeptide Y overexpression using recombinant adeno-associated viral vectors. Neurotherapeutics 6:300–306
19. Richichi C, Lin EJ, Stefanin D, Colella D, Ravizza T, Grignaschi G, Veglianese P, Sperk G, During MJ, Vezzani A (2004) Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J Neurosci 24:3051–3059
20. Bacci A, Huguenard JR, Prince DA (2002) Differential modulation of synaptic transmission by neuropeptide Y in rat neocortical neurons. Proc Natl Acad Sci U S A 99:17125–17130
21. Baraban SC (2004) Neuropeptide Y and epilepsy: recent progress, prospects and controversies. Neuropeptides 38:261–265
22. 5 receptors. Eur J Neurosci 22:1417–1430
23. 5 receptors mediate neuropeptide Y actions at excitatory synapses in area CA3 of the mouse hippocampus. J Neurophysiol 87:558–566
24. 1 receptor knock-out mice. Focus on immunohistochemical localization. Neuroscience 111:443–532
25. Meurs A, Clinckers R, Ebinger G, Michotte Y, Smolders I (2007) Sigma 1 receptor-mediated increase in hippocampal extracellular dopamine contributes to the mechanism of the anticonvulsant action of neuropeptide Y. Eur J Neurosci 26:3079–3092
26. Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y (2004) Anticonvulsant action of hippocampal dopamine and serotonin is independently mediated by D and 5-HT receptors. J Neurochem 89:834–843
27. Woldbye DP, Kokaia M (2004) Neuropeptide Y and seizures: effects of exogenously applied ligands. Neuropeptides 38:253–260
28. Meurs A, Clinckers R, Ebinger G, Michotte Y, Smolders I (2007) Clinical potential of neuropeptide Y receptor ligands in the treatment of epilepsy. Curr Top Med Chem 7:1660–1674
29. Dubé C, Brunson KL, Eghbal-Ahmadi M, Gonzalez-Vega R, Baram TZ (2005) Endogenous neuropeptide Y prevents recurrence of experimental febrile seizures by increasing seizure threshold. J Mol Neurosci 25:275–284
30. French JA, Williamson PD, Thadani VM, Darcey TM, Mattson RH, Spencer SS, Spencer DD (1993) Characteristics of medial temporal lobe epilepsy: I. Results of history and physical examination. Ann Neurol 34:774–780
31. Cendes F, Andermann F, Dubeau F, Gloor P, Evans A, Jones-Gotman M, Olivier A, Andermann E, Robitaille Y, Lopes-Cendes I (1993) Early childhood prolonged febrile convulsions, atrophy and sclerosis of mesial structures, and temporal lobe epilepsy: an MRI volumetric study. Neurology 43:1083–1087
32. Lin LC, Lee WT, Chen IJ, Yang RC (2010) Lower plasma neuropeptide Y level in patients with atypical febrile convulsions. Kaohsiung J Med Sci 26:8–12
33. Mahyar A, Ayazi P, Nazari M, Sarokhani HR, Daneshi-Kohan MM, Javadi A (2013) Lack of correlation between plasma neuropeptide Y and typical and atypical febrile seizures. Acta Med Iran 51:246–249
34. Howell OW, Silva S, Scharfman HE, Sosunov AA, Zaben M, Shatya A, McKhann G, Herzog H, Laskowski A, Gray WP (2007) Neuropeptide Y is important for basal and seizure-induced precursor cell proliferation in the hippocampus. Neurobiol Dis 26:174–188
35. Kokaia M (2011) Seizure-induced neurogenesis in the adult brain. Eur J Neurosci 33:1133–1138
36. Lerner JT, Sankar R, Mazarati AM (2008) Galanin and epilepsy. Cell Mol Life Sci 65:1864–1871
37. Mazarati AM (2004) Galanin and galanin receptors in epilepsy. Neuropeptides 38:331–343
38. Mazarati AM, Liu H, Soomets U, Sankar R, Shin D, Katsumori H, Langel U, Wasterlain CG (1998) Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus. J Neurosci 18:10070–10077
39. Mazarati AM, Halaszi E, Telegdy G (1992) Anticonvulsive effects of galanin administered into the central nervous system upon the picrotoxin-kindled seizure syndrome in rats. Brain Res 589:164–166
40. Mazarati AM, Hohmann JG, Bacon A, Liu H, Sankar R, Steiner RA, Wynick D, Wasterlain CG (2000) Modulation of hippocampal excitability and seizures by galanin. J Neurosci 20:6276–6281
41. Chepurnov SA, Chepurnova NE, Abbasova KR, Smirnova MP (1997) The neuropeptide galanin and the seizure reactions of the developing brain. Usp Fiziol Nauk 28:3–20
42. Jacoby AS, Hort YJ, Constantinescu G, Shine J, Iismaa TP (2002) Critical role for GALR1 galanin receptor in galanin regulation of neuroendocrine function and seizure activity. Brain Res Mol Brain Res 107:195–200
43. McColl CD, Jacoby AS, Shine J, Iismaa TP, Bekkers JM (2006) Galanin receptor-1 knockout mice exhibit spontaneous epilepsy, abnormal EEGs and altered inhibition in the hippocampus. Neuropharmacology 50:209–218
44. Mazarati A, Lu X, Kilk K, Langel U, Wasterlain C, Bartfai T (2004) Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure-induced neurogenesis in the dentate gyrus. Eur J Neurosci 19:3235–3244
45. Zini S, Roisin MP, Langel U, Bartfai T, Ben-Ari Y (1993) Galanin reduces release of endogenous excitatory amino acids in the rat hippocampus. Eur J Pharmacol 245:1–7
46. Zini S, Roisin MP, Armengaud C, Ben-Ari Y (1993) Effect of potassium channel modulators on the release of glutamate induced by ischaemic-like conditions in rat hippocampal slices. Neurosci Lett 153:202–205
47. 2+ channels. J Neurochem 56:739–747
48. Mazarati AM, Baldwin RA, Shinmei S, Sankar R (2005) In vivo interaction between serotonin and galanin receptors types 1 and 2 in the dorsal raphe: implication for limbic seizures. J Neurochem 95:1495–1503
49. Lin EJ, Richichi C, Young D, Baer K, Vezzani A, During MJ (2003) Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development. Eur J Neurosci 18:2087–2092
50. McCown TJ (2009) Adeno-associated virus vector-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity. Neurotherapeutics 6:307–311
51. Ferrini F, Salio C, Lossi L, Merighi A (2009) Ghrelin in central neurons. Curr Neuropharmacol 7:37–49
52. Guan XM, Yu H, Palyha OC, McKee KK, Feighner SD, Sirinathsinghji DJ, Smith RG, Van der Ploeg LH, Howard AD (1997) Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res Mol Brain Res 48:23–29
53. Portelli J, Michotte Y, Smolders I (2012) Ghrelin: an emerging new anticonvulsant neuropeptide. Epilepsia 53:585–595
54. Ataie Z, Golzar MG, Babri S, Ebrahimi H, Mohaddes G (2011) Does ghrelin level change after epileptic seizure in rats? Seizure 20:347–349
55. Gahete MD, Cordoba-Chacon J, Salvatori R, Castano JP, Kineman RD, Luque RM (2010) Metabolic regulation of ghrelin O-acyl transferase (GOAT) expression in the mouse hypothalamus, pituitary, and stomach. Mol Cell Endocrinol 317:154–160
56. Bhatt R, Bhatt S, Rameshwar P, Siegel A (2005) Long-term kindled seizures induce alterations in hematopoietic functions: role of serum leptin. Epilepsy Res 65:169–178
57. Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, Makino S, Fujimiya M, Niijima A, Fujino MA, Kasuga M (2001) Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 120:337–345
58. Obay BD, Tasdemir E, Tumer C, Bilgin HM, Sermet A (2007) Antiepileptic effects of ghrelin on pentylenetetrazole-induced seizures in rats. Peptides 28:1214–1219
59. Biagini G, Torsello A, Marinelli C, Gualtieri F, Vezzali R, Coco S, Bresciani E, Locatelli V (2011) Beneficial effects of desacyl-ghrelin, hexarelin and EP-80317 in models of status epilepticus. Eur J Pharmacol 670:130–136
60. Portelli J, Thielemans L, Ver Donck L, Loyens E, Coppens J, Aourz N, Aerssens J, Vermoesen K, Clinckers R, Schallier A, Michotte Y, Moechars D, Collingridge GL, Bortolotto ZA, Smolders I (2012) Inactivation of the constitutively active ghrelin receptor attenuates limbic seizure activity in rodents. Neurotherapeutics 9:658–672
61. Cowley MA, Smith RG, Diano S, Tschop M, Pronchuk N, Grove KL, Strasburger CJ, Bidlingmaier M, Esterman M, Heiman ML, Garcia-Segura LM, Nillni EA, Mendez P, Low MJ, Sotonyi P, Friedman JM, Liu H, Pinto S, Colmers WF, Cone RD, Horvath TL (2003) The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 37:649–661
62. Moon M, Kim S, Hwang L, Park S (2009) Ghrelin regulates hippocampal neurogenesis in adult mice. Endocr J 56:525–531
63. Xu J, Wang S, Lin Y, Cao L, Wang R, Chi Z (2009) Ghrelin protects against cell death of hippocampal neurons in pilocarpine-induced seizures in rats. Neurosci Lett 453:58–61
64. Lee J, Lim E, Kim Y, Li E, Park S (2010) Ghrelin attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. J Endocrinol 205:263–270
65. Zhang R, Yang G, Wang Q, Guo F, Wang H (2013) Acylated ghrelin protects hippocampal neurons in pilocarpine-induced seizures of immature rats by inhibiting cell apoptosis. Mol Biol Rep 40:51–58
66. Vezzani A, Hoyer D (1999) Brain somatostatin: a candidate inhibitory role in seizures and epileptogenesis. Eur J Neurosci 11:3767–3776
67. Tallent MK, Qiu C (2008) Somatostatin: an endogenous antiepileptic. Mol Cell Endocrinol 286:96–103
68. De Bundel D, Aourz N, Kiagiadaki F, Clinckers R, Hoyer D, Kastellakis A, Michotte Y, Thermos K, Smolders I (2010) Hippocampal sst(1) receptors are autoreceptors and do not affect seizures in rats. Neuroreport 21:254–258
69. Choi YS, Lin SL, Lee B, Kurup P, Cho HY, Naegele JR, Lombroso PJ, Obrietan K (2007) Status epilepticus-induced somatostatinergic hilar interneuron degeneration is regulated by striatal enriched protein tyrosine phosphatase. J Neurosci 27:2999–3009
70. Buckmaster PS, Dudek FE (1997) Neuron loss, granule cell axon reorganization, and functional changes in the dentate gyrus of epileptic kainate-treated rats. J Comp Neurol 385:385–404
71. Sun C, Mtchedlishvili Z, Bertram EH, Erisir A, Kapur J (2007) Selective loss of dentate hilar interneurons contributes to reduced synaptic inhibition of granule cells in an electrical stimulation-based animal model of temporal lobe epilepsy. J Comp Neurol 500:876–893
72. Halabisky B, Parada I, Buckmaster PS, Prince DA (2010) Excitatory input onto hilar somatostatin interneurons is increased in a chronic model of epilepsy. J Neurophysiol 104:2214–2223
73. Zhang W, Yamawaki R, Wen X, Uhl J, Diaz J, Prince DA, Buckmaster PS (2009) Surviving hilar somatostatin interneurons enlarge, sprout axons, and form new synapses with granule cells in a mouse model of temporal lobe epilepsy. J Neurosci 29:14247–14256
74. Nagaki S, Nagaki S, Minatogawa Y, Sadamatsu M, Kato N, Osawa M, Fukuyama Y (1996) The role of vasopressin, somatostatin and GABA in febrile convulsion in rat pups. Life Sci 58:2233–2242
75. Schwarzer C, Sperk G, Samanin R, Rizzi M, Gariboldi M, Vezzani A (1996) Neuropeptides-immunoreactivity and their mRNA expression in kindling: functional implications for limbic epileptogenesis. Brain Res Brain Res Rev 22:27–50
76. Hashimoto T, Obata K (1991) Induction of somatostatin by kainic acid in pyramidal and granule cells of the rat hippocampus. Neurosci Res 12:514–527
77. Vezzani A, Monno A, Rizzi M, Galli A, Barrios M, Samanin R (1992) Somatostatin release is enhanced in the hippocampus of partially and fully kindled rats. Neuroscience 51:41–46
78. Marti M, Bregola G, Morari M, Gemignani A, Simonato M (2000) Somatostatin release in the hippocampus in the kindling model of epilepsy: a microdialysis study. J Neurochem 74:2497–2503
79. Hirai K, Seki T (2000) Cerebrospinal fluid somatostatin levels in febrile seizures and epilepsy in children. Neuropeptides 34:18–24
80. Csaba Z, Richichi C, Bernard V, Epelbaum J, Vezzani A, Dournaud P (2004) Plasticity of somatostatin and somatostatin sst2A receptors in the rat dentate gyrus during kindling epileptogenesis. Eur J Neurosci 19:2531–2538
81. Perez J, Vezzani A, Civenni G, Tutka P, Rizzi M, Schupbach E, Hoyer D (1995) Functional effects of D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp-NH2 and differential changes in somatostatin receptor messenger RNAs, binding sites and somatostatin release in kainic acid-treated rats. Neuroscience 65:1087–1097
82. Vezzani A, Serafini R, Stasi MA, Vigano G, Rizzi M, Samanin R (1991) A peptidase-resistant cyclic octapeptide analogue of somatostatin (SMS 201-995) modulates seizures induced by quinolinic and kainic acids differently in the rat hippocampus. Neuropharmacology 30:345–352
83. Monno A, Rizzi M, Samanin R, Vezzani A (1993) Anti-somatostatin antibody enhances the rate of hippocampal kindling in rats. Brain Res 602:148–152
84. Mazarati AM, Telegdy G (1992) Effects of somatostatin and anti-somatostatin serum on picrotoxin-kindled seizures. Neuropharmacology 31:793–797
85. Tallent MK, Siggins GR (1997) Somatostatin depresses excitatory but not inhibitory neurotransmission in rat CA1 hippocampus. J Neurophysiol 78:3008–3018
86. Kozhemyakin M, Rajasekaran K, Todorovic MS, Kowalski SL, Balint C, Kapur J (2013) Somatostatin type-2 receptor activation inhibits glutamate release and prevents status epilepticus. Neurobiol Dis 54:94–104
87. Aourz N, De Bundel D, Stragier B, Clinckers R, Portelli J, Michotte Y, Smolders I (2011) Rat hippocampal somatostatin sst3 and sst4 receptors mediate anticonvulsive effects in vivo: indications of functional interactions with sst2 receptors. Neuropharmacology 61:1327–1333
88. Moneta D, Richichi C, Aliprandi M, Dournaud P, Dutar P, Billard JM, Carlo AS, Viollet C, Hannon JP, Fehlmann D, Nunn C, Hoyer D, Epelbaum J, Vezzani A (2002) Somatostatin receptor subtypes 2 and 4 affect seizure susceptibility and hippocampal excitatory neurotransmission in mice. Eur J Neurosci 16:843–849
89. Qiu C, Zeyda T, Johnson B, Hochgeschwender U, de Lecea L, Tallent MK (2008) Somatostatin receptor subtype 4 couples to the M-current to regulate seizures. J Neurosci 28:3567–3576
90. Calbet M, Guadano-Ferraz A, Spier AD, Maj M, Sutcliffe JG, Przewlocki R, de Lecea L (1999) Cortistatin and somatostatin mRNAs are differentially regulated in response to kainate. Brain Res Mol Brain Res 72:55–64
91. Wilson DN, Chung H, Elliott RC, Bremer E, George D, Koh S (2005) Microarray analysis of postictal transcriptional regulation of neuropeptides. J Mol Neurosci 25:285–298
92. Braun H, Schulz S, Becker A, Schroder H, Hollt V (1998) Protective effects of cortistatin (CST-14) against kainate-induced neurotoxicity in rat brain. Brain Res 803:54–60
93. Arganaraz GA, Konno AC, Perosa SR, Santiago JF, Boim MA, Vidotti DB, Varella PP, Costa LG, Canzian M, Porcionatto MA, Yacubian EM, Sakamoto AC, Jr Carrete H, Centeno RS, Amado D, Cavalheiro EA, Junior JA, Mazzacoratti MG (2008) The renin–angiotensin system is upregulated in the cortex and hippocampus of patients with temporal lobe epilepsy related to mesial temporal sclerosis. Epilepsia 49:1348–1357
94. Pereira MG, Becari C, Oliveira JA, Salgado MC, Garcia-Cairasco N, Costa-Neto CM (2010) Inhibition of the renin–angiotensin system prevents seizures in a rat model of epilepsy. Clin Sci (Lond) 119:477–482
95. Sarro GD, Paola ED, Gratteri S, Gareri P, Rispoli V, Siniscalchi A, Tripepi G, Gallelli L, Citraro R, Russo E (2012) Fosinopril and zofenopril, two angiotensin-converting enzyme (ACE) inhibitors, potentiate the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice. Pharmacol Res 65:285–296
96. Gouveia TL, Frangiotti MI, de Brito JM, de Castro Neto EF, Sakata MM, Febba AC, Casarini DE, Amado D, Cavalheiro EA, Almeida SS, Manchini MT, Araujo RC, Jr Silva JA, Naffah-Mazzacoratti MG (2012) The levels of renin–angiotensin related components are modified in the hippocampus of rats submitted to pilocarpine model of epilepsy. Neurochem Int 61:54–62
97. Tchekalarova J, Kambourova T, Georgiev V (2001) Effects of angiotensin III and angiotensin IV on pentylenetetrazol seizure susceptibility (threshold and kindling): interaction with adenosine A(1) receptors. Brain Res Bull 56:87–91
98. De Bundel D, Smolders I, Vanderheyden P, Michotte Y (2008) Ang II and Ang IV: unraveling the mechanism of action on synaptic plasticity, memory, and epilepsy. CNS Neurosci Ther 14:315–339
99. Tchekalarova J, Georgiev V (2005) Angiotensin peptides modulatory system: how is it implicated in the control of seizure susceptibility? Life Sci 76:955–970
100. Georgiev VP, Lazarova MB, Petkov VD, Kambourova TS (1986) Interactions between angiotensin II, GABA and diazepam in convulsive seizures. Neuropeptides 7:329–336
101. Georgiev VP, Lazarova MB, Kambourova TS (1995) Further evidence for the interactions between angiotensin II and GABAergic transmission in pentylenetetrazol kindling seizures in mice. Neuropeptides 28:29–34
102. Georgiev VP, Lazarova MB, Kambourova TS (1996) Effects of non-peptide angiotensin II-receptor antagonists on pentylenetetrazol kindling in mice. Neuropeptides 30:401–404
103. Oz M, Yang KH, O'donovan MJ, Renaud LP (2005) Presynaptic angiotensin II AT1 receptors enhance inhibitory and excitatory synaptic neurotransmission to motoneurons and other ventral horn neurons in neonatal rat spinal cord. J Neurophysiol 94:1405–1412
104. Loyens E, Schallier A, Chai SY, De Bundel D, Vanderheyden P, Michotte Y, Smolders I (2011) Deletion of insulin-regulated aminopeptidase in mice decreases susceptibility to pentylenetetrazol-induced generalized seizures. Seizure 20:602–605
105. Stragier B, Clinckers R, Meurs A, De Bundel D, Sarre S, Ebinger G, Michotte Y, Smolders I (2006) Involvement of the somatostatin-2 receptor in the anti-convulsant effect of angiotensin IV against pilocarpine-induced limbic seizures in rats. J Neurochem 98:1100–1113
106. Georgiev V, Gyorgy L, Getova D, Markovska V (1985) Some central effects of angiotensin II. Interactions with dopaminergic transmission. Acta Physiol Pharmacol Bulg 11:19–26
107. Tchekalarova J, Sotiriou E, Georgiev V, Kostopoulos G, Angelatou F (2005) Up-regulation of adenosine A1 receptor binding in pentylenetetrazol kindling in mice: effects of angiotensin IV. Brain Res 1032:94–103
108. Gall CM (1988) Localization and seizure-induced alterations of opioid peptides and CCK in the hippocampus. NIDA Res Monogr 82:12–32
109. Wyeth MS, Zhang N, Mody I, Houser CR (2010) Selective reduction of cholecystokinin-positive basket cell innervation in a model of temporal lobe epilepsy. J Neurosci 30:8993–9006
110. Wyeth MS, Zhang N, Houser CR (2012) Increased cholecystokinin labeling in the hippocampus of a mouse model of epilepsy maps to spines and glutamatergic terminals. Neuroscience 202:371–383
111. Iadarola MJ, Sherwin AL (1991) Alterations in cholecystokinin peptide and mRNA in actively epileptic human temporal cortical foci. Epilepsy Res 8:58–63
112. Zetler G (1980) Anticonvulsant effects of careulein and cholecystokinin octapeptide, compared with those of diazepam. Eur J Pharmacol 65:297–300
113. Kadar T, Pesti A, Penke B, Telegdy G (1984) Inhibition of seizures induced by picrotoxin and electroshock by cholecystokinin octapeptides and their fragments in rats after intracerebroventricular administration. Neuropharmacology 23:955–961
114. Deng PY, Xiao Z, Jha A, Ramonet D, Matsui T, Leitges M, Shin HS, Porter JE, Geiger JD, Lei S (2010) Cholecystokinin facilitates glutamate release by increasing the number of readily releasable vesicles and releasing probability. J Neurosci 30:5136–5148
115. Deng PY, Lei S (2006) Bidirectional modulation of GABAergic transmission by cholecystokinin in hippocampal dentate gyrus granule cells of juvenile rats. J Physiol 572:425–442
116. Gall C, Lauterborn J, Isackson P, White J (1990) Seizures, neuropeptide regulation, and mRNA expression in the hippocampus. Prog Brain Res 83:371–390
117. Gall C (1988) Seizures induce dramatic and distinctly different changes in enkephalin, dynorphin, and CCK immunoreactivities in mouse hippocampal mossy fibers. J Neurosci 8:1852–1862
118. Sperk G, Wieser R, Widmann R, Singer EA (1986) Kainic acid induced seizures: changes in somatostatin, substance P and neurotensin. Neuroscience 17:1117–1126
119. Sperk G, Lassmann H, Baran H, Seitelberger F, Hornykiewicz O (1985) Kainic acid-induced seizures: dose-relationship of behavioural, neurochemical and histopathological changes. Brain Res 338:289–295
120. Shulkes A, Harris QL, Lewis SJ, Vajda JE, Jarrott B (1988) Regional brain concentrations of neurotensin following amygdaloid kindled and cortical suprathreshold stimulation-induced seizures in the rat. Neuropeptides 11:77–81
121. Lee HK, Zhang L, Smith MD, White HS, Bulaj G (2009) Glycosylated neurotensin analogues exhibit sub-picomolar anticonvulsant potency in a pharmacoresistant model of epilepsy. ChemMedChem 4:400–405
122. Robertson CR, Flynn SP, White HS, Bulaj G (2011) Anticonvulsant neuropeptides as drug leads for neurological diseases. Nat Prod Rep 28:741–762
123. Li S, Geiger JD, Lei S (2008) Neurotensin enhances GABAergic activity in rat hippocampus CA1 region by modulating L-type calcium channels. J Neurophysiol 99:2134–2143
124. Green BR, White KL, McDougle DR, Zhang L, Klein B, Scholl EA, Pruess TH, White HS, Bulaj G (2010) Introduction of lipidization-cationization motifs affords systemically bioavailable neuropeptide Y and neurotensin analogs with anticonvulsant activities. J Pept Sci 16:486–495
125. Koneru A, Satyanarayana S, Rizwan S (2009) Endogenous opioids: their physiological role and receptors. Glob J Pharmacol 3:149–153
126. Kanamatsu T, Obie J, Grimes L, McGinty JF, Yoshikawa K, Sabol S, Hong JS (1986) Kainic acid alters the metabolism of Met5-enkephalin and the level of dynorphin A in the rat hippocampus. J Neurosci 6:3094–3102
127. McGinty JF, Kanamatsu T, Obie J, Dyer RS, Mitchell CL, Hong JS (1986) Amygdaloid kindling increases enkephalin-like immunoreactivity but decreases dynorphin-A-like immunoreactivity in rat hippocampus. Neurosci Lett 71:31–36
128. Rocha LL, Evans CJ, Maidment NT (1997) Amygdala kindling modifies extracellular opioid peptide content in rat hippocampus measured by microdialysis. J Neurochem 68:616–624
129. Mazarati A, Liu H, Wasterlain C (1999) Opioid peptide pharmacology and immunocytochemistry in an animal model of self-sustaining status epilepticus. Neuroscience 89:167–173
130. Pirker S, Gasser E, Czech T, Baumgartner C, Schuh E, Feucht M, Novak K, Zimprich F, Sperk G (2009) Dynamic up-regulation of prodynorphin transcription in temporal lobe epilepsy. Hippocampus 19:1051–1054
131. Hammers A, Asselin MC, Hinz R, Kitchen I, Brooks DJ, Duncan JS, Koepp MJ (2007) Upregulation of opioid receptor binding following spontaneous epileptic seizures. Brain 130:1009–1016
132. McDermott CM, Schrader LA (2011) Activation of kappa opioid receptors increases intrinsic excitability of dentate gyrus granule cells. J Physiol 589:3517–3532
133. Loacker S, Sayyah M, Wittmann W, Herzog H, Schwarzer C (2007) Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors. Brain 130:1017–1028
134. Simmons ML, Chavkin C (1996) Endogenous opioid regulation of hippocampal function. Int Rev Neurobiol 39:145–196
135. Wheless JW, Gibson PA, Rosbeck KL, Hardin M, O'Dell C, Whittemore V, Pellock JM (2012) Infantile spasms (West syndrome): update and resources for pediatricians and providers to share with parents. BMC Pediatr 12:108
136. Baram TZ (2007) Models for infantile spasms: an arduous journey to the Holy Grail. Ann Neurol 61:89–91
137. Brunson KL, Eghbal-Ahmadi M, Baram TZ (2001) How do the many etiologies of West syndrome lead to excitability and seizures? The corticotropin releasing hormone excess hypothesis. Brain Dev 23:533–538
138. Baram TZ, Hirsch E, Snead OC III, Schultz L (1992) Corticotropin-releasing hormone-induced seizures in infant rats originate in the amygdala. Ann Neurol 31:488–494
139. Baram TZ, Chalmers DT, Chen C, Koutsoukos Y, De Souza EB (1997) The CRF1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, non-peptide CRF receptor antagonist. Brain Res 770:89–95
140. Wang W, Dow KE, Fraser DD (2001) Elevated corticotropin releasing hormone/corticotropin releasing hormone-R1 expression in postmortem brain obtained from children with generalized epilepsy. Ann Neurol 50:404–409
141. Aldenhoff JB, Gruol DL, Rivier J, Vale W, Siggins GR (1983) Corticotropin releasing factor decreases postburst hyperpolarizations and excites hippocampal neurons. Science 221:875–877
142. Hollrigel GS, Chen K, Baram TZ, Soltesz I (1998) The pro-convulsant actions of corticotropin-releasing hormone in the hippocampus of infant rats. Neuroscience 84:71–79
143. Avishai-Eliner S, Yi SJ, Baram TZ (1996) Developmental profile of messenger RNA for the corticotropin-releasing hormone receptor in the rat limbic system. Brain Res Dev Brain Res 91:159–163
144. Baram TZ, Schultz L (1991) Corticotropin-releasing hormone is a rapid and potent convulsant in the infant rat. Brain Res Dev Brain Res 61:97–101
145. Wang W, Murphy B, Dow KE, David AR, Fraser DD (2004) Systemic adrenocorticotropic hormone administration down-regulates the expression of corticotropin-releasing hormone (CRH) and CRH-binding protein in infant rat hippocampus. Pediatr Res 55:604–610
146. Jaseja H, Jaseja B, Badaya S, Tonpay P (2012) Superior therapeutic efficacy of adrenocorticotrophic hormone (ACTH) in infantile spasms: emerging evidence. Epilepsy Behav 25:250
147. Brunson KL, Khan N, Eghbal-Ahmadi M, Baram TZ (2001) Corticotropin (ACTH) acts directly on amygdala neurons to down-regulate corticotropin-releasing hormone gene expression. Ann Neurol 49:304–312
148. Nagamitsu S, Matsuishi T, Yamashita Y, Shimizu T, Iwanaga R, Murakami Y, Miyazaki M, Hashimoto T, Kato H (2001) Decreased cerebrospinal fluid levels of beta-endorphin and ACTH in children with infantile spasms. J Neural Transm 108:363–371
149. Baram TZ, Mitchell WG, III Snead OC, Horton EJ, Saito M (1992) Brain-adrenal axis hormones are altered in the CSF of infants with massive infantile spasms. Neurology 42:1171–1175
150. Nalin A, Facchinetti F, Galli V, Petraglia F, Storchi R, Genazzani AR (1985) Reduced ACTH content in cerebrospinal fluid of children affected by cryptogenic infantile spasms with hypsarrhythmia. Epilepsia 26:446–449
151. Hauger RL, Irwin MR, Lorang M, Aguilera G, Brown MR (1993) High intracerebral levels of CRH result in CRH receptor downregulation in the amygdala and neuroimmune desensitization. Brain Res 616:283–292
152. Shumiloff NA, Lam WM, Manasco KB (2013) Adrenocorticotropic hormone for the treatment of West syndrome in children. Ann Pharmacother 47:744–754
153. O'Dowd BF, Lee DK, Huang W, Nguyen T, Cheng R, Liu Y, Wang B, Gershengorn MC, George SR (2000) TRH-R2 exhibits similar binding and acute signaling but distinct regulation and anatomic distribution compared with TRH-R1. Mol Endocrinol 14:183–193
154. Knoblach SM, Kubek MJ (1997) Changes in thyrotropin-releasing hormone levels in hippocampal subregions induced by a model of human temporal lobe epilepsy: effect of partial and complete kindling. Neuroscience 76:97–104
155. Knoblach SM, Kubek MJ (1997) Increases in thyrotropin-releasing hormone messenger RNA expression induced by a model of human temporal lobe epilepsy: effect of partial and complete kindling. Neuroscience 76:85–95
156. Kubek MJ, Meyerhoff JL, Hill TG, Norton JA, Sattin A (1985) Effects of subconvulsive and repeated electroconvulsive shock on thyrotropin-releasing hormone in rat brain. Life Sci 36:315–320
157. Takeuchi Y, Matsushita H, Kawano H, Sakai H, Yoshimoto K, Sawada T (1999) TRH increases cerebrospinal fluid concentration of kynurenine. Neuroreport 10:3601–3603
158. Deng PY, Porter JE, Shin HS, Lei S (2006) Thyrotropin-releasing hormone increases GABA release in rat hippocampus. J Physiol 577:497–511
159. Khomane KS, Meena CL, Jain R, Bansal AK (2011) Novel thyrotropin-releasing hormone analogs: a patent review. Expert Opin Ther Pat 21:1673–1691
160. Facchinetti F, Nalin A, Petraglia F, Galli V, Genazzani AR (1985) Reduced ACTH, while normal beta-endorphin CSF levels in early epileptic encephalopathies. Peptides 6:31–33
161. Henriksen SJ, Bloom FE, McCoy F, Ling N, Guillemin R (1978) Beta-endorphin induces nonconvulsive limbic seizures. Proc Natl Acad Sci U S A 75:5221–5225
162. Cain DP, Boon F, Corcoran ME (1990) Involvement of multiple opiate receptors in opioid kindling. Brain Res 517:236–244
163. Bing G, Wilson B, Hudson P, Jin L, Feng Z, Zhang W, Bing R, Hong JS (1997) A single dose of kainic acid elevates the levels of enkephalins and activator protein-1 transcription factors in the hippocampus for up to 1 year. Proc Natl Acad Sci U S A 94:9422–9427
164. Rees H, Ang LC, Shul DD, George DH, Begley H, McConnell T (1994) Increase in enkephalin-like immunoreactivity in hippocampi of adults with generalized epilepsy. Brain Res 652:113–119
165. Carrillo E, Fuente T, Laorden ML (1992) Hyperthermia-induced seizures alter the levels of methionine-enkephalin in immature rat brain. Neuropeptides 21:139–142
166. Laorden ML, Olaso MJ, Miralles FS, Puig MM (1985) Cerebrospinal fluid leucine-enkephalin-like levels in febrile convulsions. Methods Find Exp Clin Pharmacol 7:75–77
167. Tanaka T, Takeshita H, Kawahara R, Hazama H (1989) Chemical kindling with Met-enkephalin and transfer between chemical and electrical kindling. Epilepsy Res 3:214–221
168. Comer SD, Hoenicke EM, Sable AI, McNutt RW, Chang KJ, De Costa BR, Mosberg HI, Woods JH (1993) Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice. J Pharmacol Exp Ther 267:888–895
169. Yajima Y, Narita M, Takahashi-Nakano Y, Misawa M, Nagase H, Mizoguchi H, Tseng LF, Suzuki T (2000) Effects of differential modulation of mu-, delta- and kappa-opioid systems on bicuculline-induced convulsions in the mouse. Brain Res 862:120–126
170. Grecksch G, Becker A, Schroeder H, Hollt V (1999) Involvement of delta-opioid receptors in pentylenetetrazol kindling development and kindling-related processes in rats. Naunyn Schmiedebergs Arch Pharmacol 360:151–156
171. Schroeder H, Becker A, Grecksch G, Schroeder U, Hoellt V (1998) The effect of pentylenetetrazol kindling on synaptic mechanisms of interacting glutamatergic and opioid system in the hippocampus of rats. Brain Res 811:40–46
172. Lupica CR (1995) Delta and mu enkephalins inhibit spontaneous GABA-mediated IPSCs via a cyclic AMP-independent mechanism in the rat hippocampus. J Neurosci 15:737–749
173. Sperk G, Marksteiner J, Saria A, Humpel C (1990) Differential changes in tachykinins after kainic acid-induced seizures in the rat. Neuroscience 34:219–224
174. Liu H, Cao Y, Basbaum AI, Mazarati AM, Sankar R, Wasterlain CG (1999) Resistance to excitotoxin-induced seizures and neuronal death in mice lacking the preprotachykinin A gene. Proc Natl Acad Sci U S A 96:12096–12101
175. Zachrisson O, Lindefors N, Brene S (1998) A tachykinin NK1 receptor antagonist, CP-122,721-1, attenuates kainic acid-induced seizure activity. Brain Res Mol Brain Res 60:291–295
176. Liu H, Mazarati AM, Katsumori H, Sankar R, Wasterlain CG (1999) Substance P is expressed in hippocampal principal neurons during status epilepticus and plays a critical role in the maintenance of status epilepticus. Proc Natl Acad Sci U S A 96:5286–5291
177. Kato Y, Igarashi N, Hirasawa A, Tsujimoto G, Kobayashi M (1995) Distribution and developmental changes in vasopressin V2 receptor mRNA in rat brain. Differentiation 59:163–169
178. Richmond CA (2003) The role of arginine vasopressin in thermoregulation during fever. J Neurosci Nurs 35:281–286
179. Kasting NW, Veale WL, Cooper KE, Lederis K (1981) Vasopressin may mediate febrile convulsions. Brain Res 213:327–333
180. Sun Q, Pretel S, Applegate CD, Piekut DT (1996) Oxytocin and vasopressin mRNA expression in rat hypothalamus following kainic acid-induced seizures. Neuroscience 71:543–554
181. Iwanaga M, Ohno M, Katoh A, Ohbuchi T, Ishikura T, Fujihara H, Nomura M, Hachisuka K, Ueta Y (2011) Upregulation of arginine vasopressin synthesis in the rat hypothalamus after kainic acid-induced seizures. Brain Res 1424:1–8
182. Kruse H, Van Wimersma Greidanus TB, De Wied D (1977) Barrel rotation induced by vasopressin and related peptides in rats. Pharmacol Biochem Behav 7:311–313
183. Abood LG, Knapp R, Mitchell T, Booth H, Schwab L (1980) Chemical requirements of vasopressins for barrel rotation convulsions and reversal by oxytocin. J Neurosci Res 5:191–199
184. Croiset G, De Wied D (1997) Proconvulsive effect of vasopressin; mediation by a putative V2 receptor subtype in the central nervous system. Brain Res 759:18–23
185. Gulec G, Noyan B (2002) Arginine vasopressin in the pathogenesis of febrile convulsion and temporal lobe epilepsy. Neuroreport 13:2045–2048
186. Murase T, Kondo K, Otake K, Oiso Y (1993) Pituitary adenylate cyclase-activating polypeptide stimulates arginine vasopressin release in conscious rats. Neuroendocrinology 57:1092–1096
187. Chepurnova NE, Ponomarenko AA, Chepurnov SA (2002) Peptidergic mechanisms of hyperthermia-evoked convulsions in rats in early postnatal ontogenesis. Neurosci Behav Physiol 32:505–511
188. Nomura M, Ueta Y, Hannibal J, Serino R, Yamamoto Y, Shibuya I, Matsumoto T, Yamashita H (2000) Induction of pituitary adenylate cyclase-activating polypeptide mRNA in the medial parvocellular part of the paraventricular nucleus of rats following kainic-acid-induced seizure. Neuroendocrinology 71:318–326
189. Meierkord H, Shorvon S, Lightman SL (1994) Plasma concentrations of prolactin, noradrenaline, vasopressin and oxytocin during and after a prolonged epileptic seizure. Acta Neurol Scand 90:73–77
190. Mens WB, Van Wimersma Greidanus TB (1982) Hypophyseal hormone levels in blood and cerebrospinal fluid in response to histamine and pentylenetetrazol. Neuroendocrinology 35:418–423
191. Piekut DT, Pretel S, Applegate CD (1996) Activation of oxytocin-containing neurons of the paraventricular nucleus (PVN) following generalized seizures. Synapse 23:312–320
192. Greenwood RS, Fan Z, Meeker R (1997) Persistent elevation of corticotrophin releasing factor and vasopressin but not oxytocin mRNA in the rat after kindled seizures. Neurosci Lett 224:66–70
193. Carter DA, Murphy D (1993) Acute down-regulation of oxytocin and vasopressin mRNA levels following metrazole-induced seizure in the rat. Neurosci Lett 160:135–138
194. Kaplan E (1978) A generalized epileptiform convulsion after intra-amniotic prostaglandin with intravenous oxytocin infusion: a case report. S Afr Med J 53:27–29
195. Loyens E, Vermoesen K, Schallier A, Michotte Y, Smolders I (2012) Proconvulsive effects of oxytocin in the generalized pentylenetetrazol mouse model are mediated by vasopressin 1a receptors. Brain Res 1436:43–50
196. Erbas O, Yilmaz M, Korkmaz HA, Bora S, Evren V, Peker G (2013) Oxytocin inhibits pentylentetrazol-induced seizures in the rat. Peptides 40:141–144
197. Braida D, Donzelli A, Martucci R, Ponzoni L, Pauletti A, Sala M (2012) Neurohypophyseal hormones protect against pentylenetetrazole-induced seizures in zebrafish: role of oxytocin-like and V1a-like receptor. Peptides 37:327–333
198. Sala M, Braida D, Lentini D, Busnelli M, Bulgheroni E, Capurro V, Finardi A, Donzelli A, Pattini L, Rubino T, Parolaro D, Nishimori K, Parenti M, Chini B (2011) Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism. Biol Psychiatry 69:875–882
199. Knigge KM, Wagner JE (1997) Melanin-concentrating hormone (MCH) involvement in pentylenetetrazole (PTZ)-induced seizure in rat and guinea pig. Peptides 18:1095–1097
200. Parks GS, Okumura SM, Gohil K, Civelli O (2010) Mice lacking melanin concentrating hormone 1 receptor are resistant to seizures. Neurosci Lett 484:104–107
201. Palasz A, Krzystanek M, Worthington J, Czajkowska B, Kostro K, Wiaderkiewicz R, Bajor G (2012) Nesfatin-1, a unique regulatory neuropeptide of the brain. Neuropeptides 46:105–112
202. Aydin S, Dag E, Ozkan Y, Erman F, Dagli AF, Kilic N, Sahin I, Karatas F, Yoldas T, Barim AO, Kendir Y (2009) Nesfatin-1 and ghrelin levels in serum and saliva of epileptic patients: hormonal changes can have a major effect on seizure disorders. Mol Cell Biochem 328:49–56
203. Aydin S, Dag E, Ozkan Y, Arslan O, Koc G, Bek S, Kirbas S, Kasikci T, Abasli D, Gokcil Z, Odabasi Z, Catak Z (2011) Time-dependent changes in the serum levels of prolactin, nesfatin-1 and ghrelin as a marker of epileptic attacks young male patients. Peptides 32:1276–1280
204. Liu Z, Wang F, Li ZZ, Qi JH, Xu WZ, Zhang PS, Sun T (2011) Expression of neuropeptides ghrelin and nesfatin-1 in kainic acid kindling rats. Zhonghua Yi Xue Za Zhi 91:496–500
205. Romualdi P, Lesa G, Donatini A, Balboni G, Tomatis R, Ferri S (1992) Alterations in vasoactive intestinal polypeptide-related peptides after pentylenetetrazole-induced seizures in rat brain. Eur J Pharmacol 229:149–153
206. Marksteiner J, Sperk G, Maas D (1989) Differential increases in brain levels of neuropeptide Y and vasoactive intestinal polypeptide after kainic acid-induced seizures in the rat. Naunyn Schmiedebergs Arch Pharmacol 339:173–177
207. Ko FJ, Chiang CH, Liu WJ, Chiang W (1991) Somatostatin, substance P, prolactin and vasoactive intestinal peptide levels in serum and cerebrospinal fluid of children with seizure disorders. Gaoxiong Yi Xue Ke Xue Za Zhi 7:391–397
208. de Lanerolle NC, Gunel M, Sundaresan S, Shen MY, Brines ML, Spencer DD (1995) Vasoactive intestinal polypeptide and its receptor changes in human temporal lobe epilepsy. Brain Res 686:182–193
209. Bulaj G, Green BR, Lee HK, Robertson CR, White K, Zhang L, Sochanska M, Flynn SP, Scholl EA, Pruess TH, Smith MD, White HS (2008) Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities. J Med Chem 51:8038–8047
210. Veronesi MC, Kubek DJ, Kubek MJ (2007) Intranasal delivery of a thyrotropin-releasing hormone analog attenuates seizures in the amygdala-kindled rat. Epilepsia 48:2280–2286
211. Kubek MJ, Domb AJ, Veronesi MC (2009) Attenuation of kindled seizures by intranasal delivery of neuropeptide-loaded nanoparticles. Neurotherapeutics 6:359–371
212. Noé F, Vaghi V, Balducci C, Fitzsimons H, Bland R, Zardoni D, Sperk G, Carli M, During MJ, Vezzani A (2010) Anticonvulsant effects and behavioural outcomes of rAAV serotype 1 vector-mediated neuropeptide Y overexpression in rat hippocampus. Gene Ther 17:643–652
213. Sorensen AT, Kokaia M (2013) Novel approaches to epilepsy treatment. Epilepsia 54:1–10
214. McCown TJ (2010) The future of epilepsy treatment: focus on adeno-associated virus vector gene therapy. Drug News Perspect 23:281–286
215. Foti SB, Samulski RJ, McCown TJ (2009) Delivering multiple gene products in the brain from a single adeno-associated virus vector. Gene Ther 16:1314–1319
216. Pitkänen A, Schwartzkroin PA, Moshé SL (2006) Models of seizures and epilepsy. Elsevier Academic Press, Burlington
217. Wan RQ, Noguera EC, Weiss SR (1998) Anticonvulsant effects of intra-hippocampal injection of TRH in amygdala kindled rats. Neuroreport 9:677–682